DELIVERY OF NERVE GROWTH FACTOR TO THE BRAIN

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$422,381.00
Award Year:
1992
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Award Id:
16771
Agency Tracking Number:
16771
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
26 Lansdowne St, Cambridge, MA, 02139
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Phillip Friden
(617) 494-0171
Business Contact:
() -
Research Institution:
n/a
Abstract
NERVE GROWTH FACTOR (NGF) HAS BEEN SHOWN IN VITRO AND IN VIVO TO SUPPORT THE GROWTH OF BASAL FOREBRAIN CHOLINERGIC NEURONS. IN ALZHEIMER'S DISEASE, THESE CELLS UNDERGO SIGNIFICANT DEGENERATIVE CHANGES WHICH MAY BE RESPONSIBLE FOR THE COGNITIVE AND MEMORY DEFICITS ASSOCIATED WITH THIS DISORDER. BECAUSE OF THIS, NGF HAS BEEN PROPOSED AS A THERAPEUTIC FOR THE TREATMENT OF ALZHEIMER'S DISEASE. HOWEVER, THE THERAPEUTIC USE OF NGF IS HAMPERED BY THE LACK OF A NON-INVASIVE MEANS OF DELIVERY TO THE BRAIN. IT IS OUR GOAL TO DEMONSTRATE THAT A CARRIER-BASED DRUG DELIVERY SYSTEM CAN BE USED FOR THE EFFECTIVE TRANSPORT OF NGF FROM THE BLOODSTREAM TO THE BRAIN PARENCHYMA. THIS DELIVERY SYSTEM UTILIZES, AS CARRIER MOLECULES, MONOCLONAL ANTIBODIESTHAT BIND TO THE TRANSFERRIN RECEPTOR, WHICH IS FOUND IN ABUNDANCE ON THE LUMINAL SURFACE OF BRAIN CAPILLARY E ENDOTHELIAL CELLS, AND UNDERGO TRANSCYTOSIS ACROSS THE BLOOD-BRAIN BARRIER VIA THE RECEPTOR. DURING PHASE I OF THIS PROJECT, NGF WILL BE CONJUGATED TO THE CARRIER ANTIBODYAND TESTED FOR BIOLOGICAL ACTIVITY IN VITRO AND DELIVERY TO THE BRAIN IN VIVO USING A RAT MODEL. THE IN VIVO EFFICACY OF THE NGF DELIVERED USING THIS SYSTEM WILL BE EXAMINED DURING PHASE II. NERVE GROWTH FACTOR (NGF) HAS BEEN SHOWN IN VITRO AND IN VIVO TO SUPPORT THE GROWTH OF BASAL FOREBRAIN CHOLINERGIC NEURONS. IN ALZHEIMER'S DISEASE, THESE CELLS UNDERGO SIGNIFICANT DEGENERATIVE CHANGES WHICH MAY BE RESPONSIBLE FOR THE COGNITIVE AND MEMORY DEFICITS ASSOCIATED WITH THIS DISORDER. BECAUSE OF THIS, NGF HAS BEEN PROPOSED AS A THERAPEUTIC FOR THE TREATMENT OF ALZHEIMER'S DISEASE. HOWEVER, THE THERAPEUTIC USE OF NGF IS HAMPERED BY THE LACK OF A NON-INVASIVE MEANS OF DELIVERY TO THE BRAIN. IT IS OUR GOAL TO DEMONSTRATE THAT A CARRIER-BASED DRUG DELIVERY SYSTEM CAN BE USED FOR THE EFFECTIVE TRANSPORT OF NGF FROM THE BLOODSTREAM TO THE BRAIN PARENCHYMA. THIS DELIVERY SYSTEM UTILIZES, AS CARRIER MOLECULES, MONOCLONAL ANTIBODIESTHAT BIND TO THE TRANSFERRIN RECEPTOR, WHICH IS FOUND IN ABUNDANCE ON THE LUMINAL SURFACE OF BRAIN CAPILLARY E ENDOTHELIAL CELLS, AND UNDERGO TRANSCYTOSIS ACROSS THE BLOOD-BRAIN BARRIER VIA THE RECEPTOR. DURING PHASE I OF THIS PROJECT, NGF WILL BE CONJUGATED TO THE CARRIER ANTIBODYAND TESTED FOR BIOLOGICAL ACTIVITY IN VITRO AND DELIVERY TO THE BRAIN IN VIVO USING A RAT MODEL. THE IN VIVO EFFICACY OF THE NGF DELIVERED USING THIS SYSTEM WILL BE EXAMINED DURING PHASE II.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government